Who We Are
Cellmotions is a regenerative medicines process company that offers process development scale up services for stem cell production and that will provide the industry with novel bioreactor equipment based on proprietary Bach impeller technology.
We are committed to developing scale up solutions that will enable the industry to engage in commercial scale production of stem cell and other therapies that can deliver positive health outcomes to the populations of the world.
The Industry We Serve
Regenerative medicine deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. There are currently over 700 clinical trials using a variety of cell sources for treatment of debilitating diseases. The size of this market is anticipated to be valued at USD 170 Billion by 2020.
In some applications, such as autologous tissue repair or cancer immunotherapy; regenerated cells would be derived from the patient's own tissue or cells, to treat degenerative disease and cancer. In other applications, stem cells would be obtained from one or a few donors and then grown in large bioreactors into therapeutically needed doses (100 million to 1 billion per dose) for injection into many unrelated patients. As part of the growth process, these cells may be differentiated to produce the type of cell required for the particular therapy.
This field holds the promise of:
- Immunotherapy for cancer using T cells
- Cell regeneration and repair of tissues using mesenchymal stromal cells (MSC) and pluripotent stem cell derived tissues
- Organ and tissue transplantations using differentiated cells
Management Team and Advisors
Carl Bachellier is Co-Director and a founder of Cellmotions. He is a career inventor specializing in fluidics, whose experience spans many industries including automotive, semi-conductors, wastewater, ink and biotech. Notably, he has resolved complex mixing problems for a host of companies including Chrysler, Intel, Samsung, Hitachi, TSMC, Charter Semi-conductor and Kodak.
Martin Marino is Co-Director and a founder Cellmotions. He is a corporate lawyer and seasoned businessman, having previously held posts in the pharmaceutical industry as VP International Corporate Development for Apotex Inc. and as Global General Counsel for the Merck Generics Group. Mr. Marino also sits on the Boards of various biotech, pharmaceutical and medical device companies.Dr. Steve Oh Ph.D. is Scientific Advisor to Cellmotions. He is the Institute Scientist and Director of Stem Cell Bioprocessing at the Bioprocessing Technology Institute (BTI), an Institute under Singapore’s Agency for Science, Technology & Research (A*STAR). Dr. Oh was a pioneer in the field of process development for stem cell propagation, is widely known for his writings on the subject and is routinely featured as a presenter at regional and global biotech conferences.